Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

La Jolla Pharmaceutical Tries Higher-Dose Riquent Against Lupus

This article was originally published in The Pink Sheet Daily

Executive Summary

NDA could be submitted this year, company says.

You may also be interested in...



BioMarin Saves Day For La Jolla's Riquent, But All Hangs On Pivotal Trial

With new financing in hand courtesy of BioMarin, La Jolla now hopes to complete its pivotal ASPEN trial for Riquent (abetimus) in lupus nephritis and launch in the U.S. in late 2010

BioMarin Saves Day For La Jolla's Riquent, But All Hangs On Pivotal Trial

With new financing in hand courtesy of BioMarin, La Jolla now hopes to complete its pivotal ASPEN trial for Riquent (abetimus) in lupus nephritis and launch in the U.S. in late 2010

Rituxan For Lupus Misses Primary, Secondary Endpoints

Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel